SCHEMBL5889498

SCHEMBL5889498

CC(CNC(=O)C1Cc2ccc(NC(=O)c3ccc4[nH]c(C(=O)Nc5ccc6c(c5)NC(C(=O)NCC(C)N(C)C)C6)cc4c3)cc2N1)N(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.41
PLD2 O14939 1/20 0.40
PLD1 Q13393 1/20 0.40
NHERF1 O14745 1/20 0.39
NPC1 O15118 3/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
HDAC2 Q92769 2/20 0.38
PYGL P06737 6/20 0.38
EGFR P00533 2/20 0.38
PIK3CA P42336 2/20 0.38
RAB9A P51151 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
HRAS P01112 1/20 0.37
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
ITGB3 P05106 1/20 0.36
ITGA2B P08514 1/20 0.36
KMT2A Q03164 1/20 0.36
HTR1F P30939 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5889606 0.87 HRH4 (0.47) ROCK2PLD2PLD1HRASESR1
SCHEMBL5889566 0.76 HRAS (0.53) ROCK2PLD2PLD1NHERF1NPC1
SCHEMBL5889693 0.68 HRH4 (0.56) PLD2PLD1KDM4EMAPTHDAC2
SCHEMBL5889578 0.68 HTR2C (0.61) PLD2PLD1NHERF1NPC1HDAC2
SCHEMBL5889839 0.68 HDAC2 (0.56) ROCK2PLD2PLD1NHERF1NPC1
SCHEMBL8205048 0.67 NHERF1 (0.64) PLD2PLD1NHERF1NPC1KDM4E
SCHEMBL5889728 0.67 HDAC2 (0.49) ROCK2PLD2PLD1NHERF1NPC1
SCHEMBL5889619 0.66 HDAC2 (0.49) ROCK2PLD2PLD1NHERF1NPC1
SCHEMBL5889512 0.66 HDAC2 (0.50) ROCK2PLD2PLD1NHERF1NPC1
SCHEMBL5889668 0.66 HDAC2 (0.48) ROCK2PLD2PLD1NHERF1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064218-B2 Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2006-06-20 US disclosed
US-6906103-B2 Compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2005-06-14 US disclosed
US-6849713-B2 Compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2005-02-01 US disclosed
US-20030212113-A1 Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity GLAXOSMITHKLINE LLC 2003-11-13 US disclosed
WO-2003057212-A1 POLYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2003-07-17 WO disclosed
US-20030119749-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity SMITHKLINE BEECHAM CORPORATION 2003-06-26 US disclosed
US-20020037856-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119749-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity CYP51A1, MCL1, ERG28 ROCK2 3821/4885PLD2 3783/4885PLD1 2686/4885
US-20020037856-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity CYP51A1, MCL1, ERG28 ROCK2 3821/4885PLD2 3783/4885PLD1 2686/4885
US-20030212113-A1 Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity TYR, CYP51A1, ODC1 ROCK2 4226/4885PLD2 4801/4885PLD1 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.